treatment neuroendocrin carcinoma combin etoposid cisplatin evid major therapeut activ anaplast variant neoplasm forty-f patient metastat neuroendocrin tumor regimen etoposid day cisplatin day drug continu intraven infus patient well-differenti carcinoid tumor islet cell carcinoma partial object tumor regress patient anaplast neuroendocrin carcinoma partial regress complet regress overal regress rate anaplast diseas median durat regress month rang month tumor respons unrel primari site endocrin hyperfunct prior therapi experi median surviv patient anaplast tumor month favor small experi rare tumor literatur toxic patient leukopenia thrombocytopenia anemia alopecia anaplast neuroendocrin tumor respons combin etoposid cisplatin patient undifferenti carcinoma typic neuroendocrin tumor site small larg bowel pancrea stomach unknown origin consist histolog find light microscopi possibl appropri immun microscopi 